Opinion|Videos|July 9, 2024
Typical Payer Coverage Criteria for Multiple Sclerosis Therapies
Heidi Crayton, MD, discusses the typical coverage criteria requirements she encounters from payers for currently-approved therapies for multiple sclerosis.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What typical coverage criteria requirements are you seeing from payers with currently-approved therapies for multiple sclerosis (MS)?
- Do you see benefit of ICD-10 coding by different MS phenotypes vs. having only one code?
Advertisement
Related to this article
Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.
The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.
A historical review traces Sjögren disease from its early descriptions to the use of salivary gland ultrasound in diagnosis.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Postpartum navigation missed its primary goal but raised postpartum visits and primary care use among Medicaid-insured patients.
Stigma, years-long diagnostic delays, and limited follow-up after a crisis remain hurdles for people with serious mental illness, experts say.
MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.
A 39,669-patient French cohort found ustekinumab and IL-23 inhibitors carry the lowest infection risk among biologics.
Advertisement
Advertisement
Trending on AJMC
1
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
2
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
3
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
4
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
5